Ketamine in Patients Undergoing TEVAR Procedures Receiving NCI

Description

The objective of this study is to identify the opioid-sparing effects, and pain-reduction potential of low dose, sub-dissociative ketamine on patients undergoing thoracic endovascular aortic repair (TEVAR) procedures receiving naloxone continuous infusion (NCI).

Conditions

Descending Aortic Dissection, Postoperative Pain, Thoracoabdominal Aortic Aneurysm

Talk to us

Study Overview

On this page

Study Details

Study overview

The objective of this study is to identify the opioid-sparing effects, and pain-reduction potential of low dose, sub-dissociative ketamine on patients undergoing thoracic endovascular aortic repair (TEVAR) procedures receiving naloxone continuous infusion (NCI).

A Randomized, Double-blind, Placebo-controlled, Study to Identify the Opioid-sparing Effects, and Pain-reduction Potential of Low Dose Ketamine on Patients Undergoing TEVAR Procedures Receiving NCI

Ketamine in Patients Undergoing TEVAR Procedures Receiving NCI

Condition
Descending Aortic Dissection
Intervention / Treatment

-

Contacts and Locations

Lexington

University of Kentucky Medical Center, Lexington, Kentucky, United States, 40536

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * willing to give informed consent
  • * scheduled for elective thoracic aorta repair or thoracoabdominal aortic repair
  • * requires naloxone continuous infusion for spinal prophylaxis
  • * allergy to ketamine, acetaminophen, or fentanyl
  • * diagnosis of schizophrenia
  • * history of hydrocephalus or central nervous system mass
  • * incarcerated individuals
  • * pregnant or lactating individuals

Ages Eligible for Study

18 Years to 90 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Sam Tyagi,

Anna Rockich, Pharm D, STUDY_DIRECTOR, University of Kentucky

Samuel Tyagi, MD, PRINCIPAL_INVESTIGATOR, University of Kentucky

Study Record Dates

2027-08